Industry

PanTheryx’s Digestive Health Products Move into China as the Country’s Wellness Market Surges

Made in the U.S. Products—TruBiotics®, Life’s First Naturals™, and DiaResQ®—Now Sold Through Alibaba’s Tmall Global to Reach More Digestive and Immune Health-Seeking Consumers PHOENIX–(BUSINESS WIRE)–China’s dietary supplements market topped 174.3 billion yuan in 2020, increasing from about 167 billion yuan in the year prior, according to Statista. As China’s interest in healthy lifestyles and supplements … [Read more…]

Fresenius Kabi Selected to Exhibit the Ivenix Infusion System at Vizient Innovative Technology Exchange

LAKE ZURICH, Ill.–(BUSINESS WIRE)–#FreseniusKabi–Fresenius Kabi has been selected to exhibit the Ivenix Infusion System at the Vizient Innovative Technology Exchange. Vizient, Inc, the nation’s largest member-driven health care performance improvement company, will hold the Exchange on October 17, 2022, in Dallas. The annual Innovative Technology Exchange offers selected suppliers the opportunity to demonstrate their technologies … [Read more…]

Employees Continue to Struggle With Stress, While Awareness, Utilization of Wellbeing Programs in the Workplace Remains Low

International survey by Alight, Business Group on Health identifies how companies can amplify wellbeing benefits LINCOLNSHIRE, Ill.–(BUSINESS WIRE)–While employees across the United States and Europe continue to report high levels of stress, a surprising percentage do not take full advantage of their workplace’s wellbeing initiatives, despite employers’ continued prioritization of these programs, a new survey … [Read more…]

Trialbee Introduces Trialbee Honey™ Analytics, Real-Time Recruitment and Enrollment Monitoring at DPHARM 2022

CHAPEL HILL, N.C. & MALMO, Sweden–(BUSINESS WIRE)–Trialbee, the leader in data and technology-based patient recruitment and enrollment for clinical trials, will introduce a powerful real-time monitoring module now available in its flagship SaaS-based Trialbee Honey™ platform, at DPHARM 2022 on September 13 in Boston, MA. Trialbee CEO Matt Walz will present Honey for clinical operations … [Read more…]

Edifecs Launches Solution to Automate Prior Authorization at the Point of Care

Leveraging AI and NLP from recent acquisitions and FHIR® standards, Edifecs solves the prior authorization challenge for payers and providers BELLEVUE, Wash.–(BUSINESS WIRE)–Edifecs, Inc., a global health information technology solutions company, today announced a new solution that fully automates prior authorization at the point of care, leading to improved member experiences, enhanced outcomes, ongoing compliance, … [Read more…]

Consortium of Independent Immunology Clinics (CIIC) welcomes the addition of Allergy Partners, PLLC as a New Member

IRVING, Texas & ASHEVILLE, N.C.–(BUSINESS WIRE)–The Consortium of Independent Immunology Clinics (CIIC), a professional medical organization comprised of select Board-Certified Allergists and Immunologists in private practice in 21 states throughout the USA, is proud to announce the addition of Allergy Partners, PLLC as its 25th member to the network. Allergy Partners is the nation’s largest … [Read more…]

Aerie Pharmaceuticals to Host Key Opinion Leader Event on Dry Eye Disease: Current Landscape, Unmet Needs, and Emerging Treatment Options

Webinar to be held Friday, September 23, 2022 @ 10 a.m. ET DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today announced that it will host a Key Opinion Leader (KOL) webinar on Friday, September 23, 2022 from 10:00 a.m. – 11:30 … [Read more…]

WCG IRB Expands Phase I Review Services, Partners With Dr. Vince Clinical Research

PRINCETON, N.J. & OVERLAND PARK, Kan.–(BUSINESS WIRE)–WCG, the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the expansion of its Phase I review services, providing purpose-built operations for Phase I investigators. Launched in conjunction with the opening of Dr. Vince Clinical Research’s (DVCR) industry-leading, green-designed research … [Read more…]

Clovis Oncology Submits Applications for Rubraca® Label Expansion in the US and European Union as First-line Maintenance Treatment in Women with Advanced Ovarian Cancer

Submissions based on data from the Phase 3 ATHENA trial evaluating Rubraca monotherapy versus placebo (ATHENA-MONO) presented at ASCO 2022 The ATHENA-MONO trial met its primary endpoint, showing Rubraca monotherapy versus placebo improved progression-free survival (PFS) by investigator assessment in both populations in the primary efficacy analyses: HRD-positive and all patients randomized (ITT) Safety of … [Read more…]

METiS Announces Pan-RAF Inhibitor License Agreement with Voronoi

CAMBRIDGE, Mass.–(BUSINESS WIRE)–METiS Therapeutics, a Boston-area company integrating drug discovery and delivery with AI and machine learning, today announced they have entered a license agreement with Voronoi, Inc., a Korean company focused on precision medicine. Under the terms of this license agreement, METiS will receive exclusive license to develop and commercialize Voronoi’s pan-RAF inhibitor program … [Read more…]